Table 2 Trials conducted outside China
Study ID | Location | Drug | Combination therapy | Participants in placebo groups, N | Average age, years | Gender, male, % | Duration of diabetes, years | Baseline HbA1c, % | Change of HbA1c in placebo groups, % | Duration, weeks | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Rosenstock [20] | non-China | Alogliptin | Insulin | 130 | 55 | 48 | 12.2 | 9.30 | -0.13 | 26 | 5 |
Nauck [21] | non-China | Alogliptin | Metformin | 104 | 56 | 48 | 6.0 | 8.00 | -0.10 | 26 | 5 |
Raz [22] | non-China | Sitagliptin | / | 103 | 55 | 63 | 4.7 | 8.00 | 0.12 | 18 | 4 |
Aschner [23] | non-China | Sitagliptin | / | 244 | 54 | 51 | 4.6 | 8.00 | 0.18 | 24 | 4 |
Hanefeld [24] | non-China | Sitagliptin | / | 111 | 56 | 63 | 3.3 | 7.60 | 0.12 | 12 | 4 |
Goldstein [25] | non-China | Sitagliptin | Metformin | 176 | 54 | 53 | 4.6 | 8.70 | 0.17 | 24 | 4 |
Charbonnel [26] | non-China | Sitagliptin | Metformin | 237 | 55 | 60 | 6.6 | 7.98 | -0.02 | 24 | 4 |
Raz [27] | non-China | Sitagliptin | Metformin | 94 | 56 | 42 | 7.3 | 9.10 | 0.00 | 30 | 5 |
Rosenstock [28] | non-China | Sitagliptin | Pioglitazone | 178 | 57 | 58 | 6.1 | 8.02 | -0.15 | 24 | 4 |
Hermansen [29] | non-China | Sitagliptin | Glimepiride, Metformin | 219 | 56 | 53 | 9.3 | 8.34 | 0.28 | 24 | 5 |
Vilsbøll [30] | non-China | Sitagliptin | Insulin | 319 | 57 | 53 | 12.0 | 8.60 | 0.00 | 24 | 5 |
Scott [31] | non-China | Sitagliptin | / | 125 | 55 | 62 | 4.8 | 7.90 | 0.23 | 12 | 5 |
Scott [32] | non-China | Sitagliptin | Metformin | 92 | 55 | 59 | 5.4 | 7.70 | -0.22 | 18 | 4 |
Ristic [33] | non-China | Vildagliptin | / | 58 | 55 | 57 | 2.3 | 7.76 | -0.13 | 12 | 3 |
Dejager [34] | non-China | Vildagliptin | / | 94 | 52 | 48 | 1.6 | 8.40 | -0.30 | 24 | 4 |
Pi-Sunyer [35] | non-China | Vildagliptin | / | 92 | 52 | 54 | 2.5 | 8.50 | 0.00 | 24 | 4 |
Bosi [36] | non-China | Vildagliptin | Metformin | 130 | 55 | 53 | 6.2 | 8.30 | 0.20 | 24 | 3 |
Garber [37] | non-China | Vildagliptin | Pioglitazone | 138 | 55 | 51 | 4.8 | 8.70 | -0.30 | 24 | 4 |
Garber [38] | non-China | Vildagliptin | Glimepiride | 144 | 58 | 58 | 7.8 | 8.50 | 0.07 | 24 | 5 |
Fonseca [39] | non-China | Vildagliptin | Insulin | 152 | 59 | 55 | 14.9 | 8.40 | -0.20 | 24 | 4 |
Defronzo [40] | non-China | Saxagliptin | Metformin | 179 | 55 | 54 | 6.7 | 8.10 | 0.13 | 24 | 4 |
Del Prato [41] | non-China | Linagliptin | / | 167 | 54 | 47 | / | 8.00 | 0.25 | 24 | 4 |
Taskinen [42] | non-China | Linagliptin | Metformin | 177 | 57 | 57 | / | 8.02 | 0.15 | 24 | 4 |
Moses [43] | non-China | Sitagliptin | Sulfonylurea, Metformin | 212 | 55.4 | 46 | 8 | 8.4 | -0.16 | 24 | 5 |
Laakso [44] | non-China | Linagliptin | Glimepiride | 120 | 66.6 | 63.4 | / | 8.1 | -0.11 | 12 | 3 |
White [45] | non-China | Saxagliptin | Metformin | 84 | 56.6 | 52.3 | 6.2 | 7.97 | -0.22 | 12 | 5 |
Moses [46] | non-China | Saxagliptin | Sulfonylurea, Metformin | 127 | 56.8 | 57.8 | / | 8.2 | -0.08 | 24 | 4 |
Bajaj [47] | non-China | Linagliptin | Metformin, Pioglitazone | 89 | 55.2 | 55.1 | / | 8.47 | -0.27 | 24 | 4 |
Fonseca [48] | non-China | Sitagliptin | Metformin, Pioglitazone | 153 | 56.4 | 62.8 | 10.2 | 8.6 | -0.4 | 26 | 5 |
Kothny [49] | non-China | Vildagliptin | Insulin | 221 | 59.1 | 52 | 13.2 | 8.8 | -0.1 | 24 | 4 |
Dobs [50] | non-China | Sitagliptin | Metformin, Osiglitazone | 88 | 54.8 | 60 | 9.4 | 8.7 | -0.3 | 18 | 5 |
Lewin [51] | non-China | Linagliptin | Sulfonylurea | 82 | 56.2 | 61.9 | / | 8.6 | -0.07 | 18 | 4 |
Barnett [52] | non-China | Linagliptin | / | 73 | 56.7 | 43.4 | / | 8.1 | 0.21 | 18 | 5 |
Forst [53] | non-China | Linagliptin | Metformin | 70 | 60.1 | 62 | 6.2 | 8.4 | 0.24 | 12 | 4 |
Nowicki [54] | non-China | Saxagliptin | / | 83 | 66.2 | 48.2 | 18.2 | 8.09 | -0.44 | 12 | 5 |
Gomis [55] | non-China | Linagliptin | Pioglitazone | 128 | 57.1 | 65.4 | / | 8.58 | -0.56 | 24 | 4 |
Hollander [56] | non-China | Saxagliptin | Thiazolidinedione | 180 | 54.1 | 46.2 | 5.1 | 8.2 | -0.3 | 24 | 4 |
Pratley [57] | non-China | Alogliptin | Glyburide | 99 | 57.1 | 51.5 | 7.7 | 8 | 0.01 | 26 | 4 |
Pratley [58] | non-China | Vildagliptin | / | 26 | 52.8 | 50 | 3.5 | 8.1 | 0 | 12 | 5 |
Nonaka [59] | Japan | Sitagliptin | / | 76 | 55 | 66 | 4.1 | 7.70 | 0.41 | 12 | 5 |
Kikuchi [60] | Japan | Vildagliptin | / | 20 | 62 | 55 | 7.2 | 7.30 | 0.28 | 12 | 4 |
Iwamoto [61] | Japan | Sitagliptin | / | 73 | 60 | 69 | 6.4 | 7.74 | 0.28 | 12 | 4 |
Kikuchi [62] | Japan | Vildagliptin | Glimepiride | 100 | 60 | 69 | 9.8 | 8.00 | -0.06 | 12 | 4 |
Kaku [63] | Japan | Alogliptin | Pioglitazone | 115 | 60 | 66 | 6.7 | 7.92 | -0.19 | 12 | 4 |
Kashiwagi [64] | Japan | Sitagliptin | Pioglitazone | 68 | 59 | 72 | 7.6 | 8.00 | 0.40 | 12 | 5 |
Seino [65] | Japan | Alogliptin | Voglibose | 75 | 62 | 64 | 7.5 | 8.12 | 0.04 | 12 | 5 |
Kawamori [66] | Japan | Linagliptin | / | 80 | 60 | 71 | 5.0 | 7.95 | 0.63 | 12 | 4 |
Seino [67] | Japan | Alogliptin | Metformin | 100 | 52 | 72 | 6.0 | 8.00 | 0.21 | 12 | 5 |
Seino [68] | Japan | Alogliptin | Sulfonylurea | 103 | 60 | 69 | 9.4 | 8.62 | 0.35 | 12 | 4 |
Kadowaki [69] | Japan | Sitagliptin | Metformin | 72 | 57 | 68 | 7.3 | 8.40 | 0.30 | 12 | 5 |
Kaku [70] | Japan | Alogliptin | Insulin | 89 | 62 | 53 | 14.5 | 8.43 | -0.31 | 12 | 4 |
Odawara [71] | Japan | Vildagliptin | Metformin | 70 | 58 | 69 | 7.0 | 8.00 | -0.10 | 12 | 4 |
Hirose [72] | Japan | Vildagliptin | Insulin | 75 | 60.1 | 71.2 | 12.9 | 8.1 | -0.11 | 12 | 5 |
Tajima [73] | Japan | Sitagliptin | Voglibose | 63 | 58.6 | 71.5 | / | 7.9 | 0.2 | 12 | 4 |
Kadowaki [74] | Japan | Sitagliptin | Insulin | 128 | 60.2 | 58.4 | 14 | 8.9 | 0.3 | 16 | 4 |
Tajima [75] | Japan | Sitagliptin | Glimepiride | 64 | 61 | 58.2 | 7.9 | 8.3 | 0.3 | 12 | 5 |